AbbVie Biotech Ventures

AbbVie Biotech Ventures — now operating as AbbVie Ventures — is the corporate venture arm of AbbVie, the global biopharmaceutical company. Founded in 2009 as Abbott Biotech Ventures and based in North Chicago, Illinois, with team members across Cambridge, San Francisco, and Oxford, the firm focuses exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Led by Vice President Adam Houghton and a four-person team, AbbVie Ventures has built a portfolio of 96 investments across oncology, immunology, neuroscience, eye care, and aesthetics — the same therapeutic areas in which AbbVie has established global commercial and scientific leadership. The firm invests at Seed and Series A stages with checks of $3 million to $30 million, backing companies including DISCO Pharmaceuticals, Zag Bio, and Soufflé Therapeutics across drug discovery, drug delivery, and therapeutic devices. The portfolio reflects a deliberate focus on the earliest translational science, where AbbVie's deep biological expertise can add the most differentiated value to founders navigating target validation and preclinical development. AbbVie Ventures gives portfolio companies access to AbbVie's scientific infrastructure: world-class drug discovery platforms, development and regulatory expertise across multiple global markets, and commercial capabilities in immunology and oncology built over decades. This combination of early-stage risk appetite with large-pharma scientific resources positions AbbVie Ventures as a differentiated partner for founders working at the frontier of biopharmaceutical innovation.